Up to 43% increase in developing COVID antibodies after third dose


Individuals under the age of 65 who are immunosuppressed developed 43% more antibodies after receiving a third shot of the Pfizer coronavirus vaccine than they did after getting the second shot, according to a study released Friday by Tel Aviv Sourasky Medical Center.

The study was conducted among 240 immunosuppressed patients who had taken the third dose since the government approved the move last month.

According to the researchers, only 25% of organ transplant patients had an antibody response to the vaccine after their first and second doses. After a third vaccine, some 50% responded.

Similarly, among hematologic patients, one-third more patients responded to the third versus the second dose.